Study Progression on Non-small Cell Lung Cancer with EGFR Mutation
Treated by Immune Checkpoint Inhibitors / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 641-648, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-772388
ABSTRACT
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquired resistance. In recent years, breakthroughs in inhibitors of programmed death-1 (PD-1) and its ligand (PD1 ligand, PD-L1) have rapidly changed the therapeutic model of NSCLC. Recent studies have shown that the efficacy of immune checkpoint inhibitors in EGFR-mutant NSCLC patients is not satisfactory, which might be caused by low PD-L1 expression, inhibitory immune microenvironment and low tumor mutation load. This review will elaborate the immune microenvironment of NSCLC patients with EGFR mutation, the latest study progression of immune checkpoint inhibitors and its combined with TKI, expecting to bring new hopes for the treatment of EGFR-mutant NSCLC patients.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Quimioterapia
/
Alergia e Inmunología
/
Terapia Molecular Dirigida
/
Receptores ErbB
/
Genética
/
Sistema Inmunológico
/
Neoplasias Pulmonares
/
Métodos
/
Mutación
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS